Addus HomeCare (NASDAQ:ADUS) Reports Q2 CY2026 In Line With Expectations

Addus HomeCare (NASDAQ: ADUS) reported Q2 CY2026 results. Revenue rose 8% year on year to $377.4 million, matching Wall Street expectations. Non-GAAP adjusted EPS was $1.73, up from $1.49 a year earlier and 1.9% above consensus. Analysts expect full-year EPS to rise from $6.68 to $7.20.

Original reporting
Published Aug 3, 2026, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 10:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Addus HomeCare (NASDAQ:ADUS) Reports Q2 CY2026 In Line With Expectations — source image
Decision brief

The 30-second read

$ADUSNeutralMed
01

Why it matters

Q2 results were described as in line on revenue but slightly ahead on adjusted EPS, with margins stable; the market reaction was negative and the forward revenue growth outlook was projected to decelerate.

02

Market read

Traders can use the reported revenue/EPS and the stated deceleration in expected revenue growth to reassess near-term valuation and earnings trajectory.

03

What to watch

Average billable patients rose to 51,097 while revenue grew slower, implying pricing pressure; traders may focus on whether that trend reverses in subsequent quarters.

Relevance 7/10Novelty 6/10Timing: after-hours/next-session reaction to Q2 results (stock down 2.6% immediately following)

Background

Addus HomeCare serves about 66,000 clients across 22 states, focused on dual-eligible Medicare and Medicaid beneficiaries.

Company-level read

Ticker impact

$ADUSNeutralMedium confidence
Context

Addus HomeCare reported Q2 CY2026 revenue of $377.4M (+8% YoY) and adjusted EPS of $1.73, beating consensus by 1.9%.

Expected impact

Near-term volatility likely persists; follow-through depends on whether investors re-rate the decelerating revenue outlook and patient mix.

Evidence & confidence

The article provides hard earnings datapoints (revenue, EPS, margin stability) plus a same-article price reaction (down 2.6%), and notes analyst expectations for revenue growth to slow to 5.4% over 12 months.

Market effects

Home healthcare demand appears resilient but the cited 12-month revenue growth deceleration may temper sector multiple expectations.

No specific regional read-through beyond the company’s 22-state footprint.

Limited, as this is company-specific earnings with no cross-border catalyst described.

Counterpoint

The EPS beat and stable adjusted operating margin (11.5%) could indicate quality earnings; the selloff may reflect positioning rather than deteriorating fundamentals.

Key entities

  • Addus HomeCare

    Home healthcare provider reporting Q2 CY2026 revenue, adjusted EPS, margins, and patient metrics.

  • Wall Street consensus

    Analysts’ revenue and EPS expectations referenced for the beat/in-line assessment.

Related articles

$ADUSHighAI 9/10

Addus Dips on Buying AccentCare

Addus HomeCare (ADUS) agreed to buy AccentCare's personal care division for $275M, excluding NY operations. The deal adds 13,700 customers in 10 states, boosting revenue by $280M (19%) and is expected to be accretive. Addus will fund the acquisition with revolver and cash. CEO Dirk Allison called it aligned with growth plans.

$ADUSMed

The Bull Case For Addus HomeCare (ADUS) Could Change Following COO Leadership Shift - Learn Why

Addus HomeCare (ADUS) announced COO Heather Dixon's departure and Brad Bickham's return as interim COO. Bickham's past experience in acquisitions and platform building may influence the company's growth strategy. Key risks include reimbursement exposure to Medicare and Medicaid, while Q2 2026 debt reduction to $64.3M suggests potential for larger acquisitions. Analysts project $1.7B revenue and $142.2M earnings by 2029, with varying views on policy and labor risks.

$RLGTMed

Why Radiant Logistics Stock Topped the Market on Tuesday

Radiant Logistics (RLGT) stock rose nearly 20% after reporting fiscal Q4 revenue of $261M (up 19% YoY) and GAAP net income of $7.5M (up 53% YoY), beating analyst estimates. The company attributed gains to increased U.S. forwarding and international airfreight volumes. However, it warned of global economic uncertainty and potential market volatility.

$ORCLMedAI 9/10

A $90 Billion Reason to Buy Oracle Stock Now

Oracle reported Q1 FY2027 earnings, beating expectations with $19.35B revenue (up 29.6% YoY) and $1.92 adjusted EPS (up 30.6% YoY). Cloud revenue surged 61.5% to $11.6B, with OCI growing 121% YoY. Oracle expects Q2 revenue growth of 30-34% and full-year revenue of at least $90B. Analysts maintain bullish views, with an average price target of $247.19.